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Abstract
Background: Systemic inflammation during implant of a durable left ventricular assist device (LVAD) may
contribute to adverse outcomes. We investigated the association of the preoperative inflammatory markers with
subsequent right ventricular failure (RVF).
Materials and methods: Prospective data was collected on 489 patients from 2003 through 2017 who underwent
implantation of a durable LVAD. Uni- and multivariable correlation with leukocytosis was determined using linear and
binary logistic regression. The population was also separated into low (< 10.5 K/ul, n = 362) and high (> 10.5 K/ul, n = 127)
white blood cell count (WBC) groups. Mantel-Cox statistics was used to analyze survival data.
Results: Postop RVF was associated with a higher preop WBC (11.3 + 5.7 vs 8.7 + 3.1) and C-reactive protein (CRP, 5.6 + 4.4
vs 3.3 + 4.7) levels. Multivariable analysis identified an independent association between increased WBC preoperatively with
increased lactate dehydrogenase (LDH, P< 0.001), heart rate (P< 0.001), CRP (P= 0.006), creatinine (P= 0.048), and INR (P= 0.
049). The high WBC group was more likely to be on preoperative temporary circulatory support (17.3% vs 6.4%, P < 0.001)
with a trend towards greater use of an intra-aortic balloon pump (55.9% vs 47.2%, P= 0.093). The high WBC group had
poorer mid-term survival (P= 0.042).
Conclusions: Postop RVF is associated with a preoperative pro-inflammatory environment. This may be secondary to the
increased systemic stress of decompensated heart failure. Systemic inflammation in the decompensated heart failure may
contribute to RVF after LVAD implant.
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Introduction
Inflammatory mediators are known to contribute to the
development and progression of heart failure [1, 2] In
the setting of durable left ventricular assist device
(LVAD) implantation, postoperative right ventricular
failure (RVF) complicates 9–44% of implants. This is as-
sociated with a greater incidence of morbidity, decreased
survival, greater demands on resources and worse long
term outcomes [3, 4]. While the majority of studies have
focused on the hemodynamic contributions to the right
ventricular dysfunction (RVD) [5], the etiology of RVF is
likely a complex interaction of mechanical burden with
underlying ventricular biology.
There is gathering evidence to implicate the immune
response in heart failure pathophysiology [6]. Decreased
chemokine receptor expression has been associated with a
greater incidence of right heart failure following durable
mechanical circulatory support (MCS), and greater mortality
at 1 year [7]. Pre-LVAD inflammatory status also has signifi-
cant prognostic implications. Higher IL-6 levels post-
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LVAD implantation is associated with longer ICU stay,
hospitalization and higher Sequential Organ Failure Assess-
ment (SOFA) score after 1 week correlating with greater
multi-organ dysfunction [8]. Postoperatively, elevated IL-6
levels during the early post-LVAD implant period was associ-
ated with death from multi-organ dysfunction, and mono-
cyte activation was proposed as a critical mechanism [9].
While these cytokine and chemokine markers of inflam-
mation are important for prognosis, they have limited
availability in a clinical setting. There is also scarce long
term follow up data associated with these inflammatory
markers. Therefore, this study examines the white blood
count (WBC) and C-reactive protein (CRP), two com-
monly measured lab values, to determine their prognostic
value for patients undergoing durable LVAD implantation.
Methods
Patients
This study was approved by the University of Michigan
Institutional Review Board (IRB#HUM00135533). A wai-
ver of informed consent was approved by the University
of Michigan IRB. We conducted a retrospective review of
prospectively collected data from 489 total patients from
the University of Michigan Mechanical Circulatory Sup-
port Registry (IRB#HUM00020274) who underwent con-
tinuous flow LVAD (cfLVAD) implantation at the from
January 1, 2003 to June 1, 2017. We separated patients
into a preoperative groups of low WBC (< 10.5 K/uL,
n = 362) and high WBC (> 10.5 K/uL, n = 127). We ex-
cluded patients who underwent pulsatile durable LVADs
in our study since these have been largely replaced by pul-
satile flow devices and carry a very different postoperative
outcomes and complication profile. We included only pa-
tients aged 18 years or older and also included patients
who needed postoperative biventricular support.
Follow up
Survival and heart transplant data was available for all 489
patients in this study who underwent cfLVAD implantation.
These were obtained through detailed prospective clinical
follow-up. Censoring was performed at the time of heart
transplantation or device explant (without replacement) for
myocardial recovery or device complication or device inacti-
vation (device not removed). Longest follow-up was 12.8
years with a total follow up of 996.8 patient years. Median
follow up was 1.32 (IQR= 2.25) years with a mean follow up
of 2.0 + 2.1 years.
Right ventricular failure defined as a central venous pres-
sure > 18mmHg with a cardiac index < 2.0 l/min/m2 in the
absence of tamponade, ventricular arrhythmias or pneumo-
thorax requiring RVAD or inhaled pulmonary vasodilator
(e.g. nitric oxide) or inotropic therapy for > 1week at any
time following LVAD implantation [10]. Only postoperative
RVF occurring during the index hospitalization following
LVAD implantation was considered. Device infection is per
criteria established by the Interagency Registry for Mechanic-
ally Assisted Circulatory Support (INTERMACS) [11].
Briefly, cutaneous site infections are defined as pain, ery-
thema or purulent drainage at the driveline site with positive
skin cultures. LVAD infection are identified with positive
blood cultures combined with fever and leukocytosis not ex-
plained by other potential causes.
Statistical methods
The Pearson chi square test or Fisher’s exact test was
used to analyze categorical variables. Student’s t-test was
used to compare continuous variables. Uni- and multi-
variable correlation with leukocytosis was determined
using linear and binary logistic regression. Kaplan-Meier
Survival analysis with Mantel-Cox statistics was used to
analyze survival data. Statistical analysis was performed
using the Statistical Package for the Social Sciences soft-
ware (SPSS Inc., Chicago, IL).
Results
Preoperative laboratory parameters and patient
demographics
Patients with preoperative WBC > 10.5 K/μL had a mean
WBC of 13.20 + 3.56 and those with WBC < 10.5 K/μL had
a mean WBC of 7.38 + 1.65 (Table 1, P < 0.001). The high
WBC group also had a higher level of another inflammatory
marker CRP (P < 0.001). The lower serum Na+ in this group
(P= 0.004) was also consistent with a worse degree of heart
failure. Greater hepatic impairment was also observed in the
in the high WBC group along with a higher total bilirubin
(P= 0.005), PT (P= 0.002) and INR (P= 0.013). No difference
in preoperative serum creatinine (P=0.273) or mixed venous
oxygen saturation (P=0.953) was seen (Table 1). Interestingly,
the high WBC group was younger (51.21 + 13.01 vs
56.53 + 12.96, P< 0.001) and had a higher BMI (P=0.005).
No differences were seen in other demographic variables or
comorbidities (P> 0.05) although there was a trend toward
greater use of preoperative CRT-D in the high WBC group
(P=0.063) (Table 1).
Cardiac and hemodynamic characteristics
The high WBC group (Table 2) had a higher heart rate
(94.91 + 19.11 vs 86.13 + 16.72, P < 0.001 bpm), right atrial
pressure (9.84 + 5.29 vs 8.63 + 4.88mmHg, P = 0.019) and
a lower right ventricular stroke work index (551.5 + 226.7
vs 615.5 + 269.1 g/m/m2/beat, P = 0.011). The high WBC
group had a higher acuity INTERMACS profile (Table 2).
There was no difference in left ventricular ejection frac-
tion, right ventricular function or valvular characteristics
between the 2 groups (P > 0.05). The high WBC group
(Table 3) was more likely to be bridged to transplant
(70.1%) while the low WBC group was more likely to be
destination therapy (41.7%, P = 0.019). Patients in the high
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WBC group were more likely to be on preoperative tem-
porary circulatory support (TCS, 17.3% vs 6.4%, P < 0.001)
and be on it for a longer period of time (6 vs 4 days,
P = 0.022). Similarly, the high WBC group had a trend for
more IABP (55.9% vs 47.2%, P = 0.093), and also for a lon-
ger duration (median of 2 vs 1 days, P = 0.012). Multivari-
able analysis identified an independent association
between increased WBC preoperatively with increased
LDH (R = 0.389, P < 0.001), heart rate (R = 0.243,
P < 0.001), CRP (R = 0.345, P = 0.006), creatinine
(R = 0.119, P = 0.048), and INR (R = 0.164, P = 0.049).
Operative characteristics and postoperative outcomes
Approximately a quarter of the patients underwent
redo-sternotomy with no difference in redo-sternotomies
between the 2 groups (P = 0.220, Table 4). There was no
difference in the incidence of concomitant procedures,
duration of CPB, or LVADs (P > 0.05). There was no dif-
ference in the distribution of valvular regurgitant path-
ology between the 2 groups (Table 3). There was also no
difference in concomitant valvular operations in the 2
groups (Table 4, P > 0.4). Mitral valve intervention was
uncommon in our practice as its utility has remained un-
clear. Aortic valve intervention was performed for moder-
ate to severe AI. Tricuspid valve procedures to improve
competence was used for moderate to severe TR. In the
low and high WBC groups, the proportion of patients
with moderate or greater TR was 42.3 and 44.9% respect-
ively. Moderate TR in the low and high WBC group were
28.1 and 33.9% respectively. For the high and low WBC
groups respectively, there were no differences in the pro-
portion of intrapericardial (55 (43.3) vs 143 (39.5%)) or
Table 1 Patient Demographics and Preoperative Laboratory Results
WBC < 10.5 K/μL (n = 362) WBC > 10.5 K/μL (n = 127) P Value
Age (years) 56.53 + 12.96 51.21 + 13.01 <0.001
Male 284 (78.5%) 99 (78.0%) 0.906
Height (cm) 174.79 + 9.76 173.50 + 10.13 0.205
Weight (kg) 84.72 + 20.87 87.91 + 23.66 0.154
BMI 27.61 + 5.99 29.62 + 9.04 0.005
Hypertension 179 (49.4%) 54 (42.5%) 0.179
Diabetes 125 (34.5%) 41 (32.3%) 0.645
Stroke or TIA 44 (12.2%) 16 (12.6%) 0.896
Carotid Disease 27 (7.5%) 8 (6.3%) 0.663
Hyperlipidemia 222 (61.3%) 71 (55.9%) 0.284
Atrial Fibrillation 81 (22.4%) 28 (22.0%) 0.939
Dialysis 0 (0.0%) 1 (0.8%) 0.091
ICD 305 (84.3%) 100 (78.7%) 0.156
CRT-D 180 (52.5%) 53 (42.7%) 0.063
WBC (K/uL) 7.38 + 1.65 13.20 + 3.56 <0.001
CRP (mg/dL) 2.80 + 4.05 5.29 + 6.04 <0.001
Hb (g/dL) 11.79 + 8.14 11.22 + 2.18 0.433
Na (mmol/L) 134.30 + 4.39 132.95 + 4.92 0.004
Cl (mmol/L) 99.28 + 5.69 96.24 + 6.29 <0.001
HCO3 (mmol/L) 27.72 + 3.76 28.76 + 4.39 0.010
BUN (mg/dL) 29.73 + 13.90 34.58 + 17.17 0.002
Cr (mg/dL) 1.31 + 0.51 1.37 + 0.50 0.273
BNP (pg/mL) 911.52 + 996.64 983.53 + 1034.26 0.493
Alk Phos (IU/L) 100.40 + 43.96 102.63 + 59.18 0.655
Total Bili (mg/dL) 1.11 + 0.67 1.43 + 1.21 0.005
PT (seconds) 11.61 + 1.11 12.05 + 1.88 0.002
INR 1.11 + 0.13 1.16 + 0.20 0.013
Uric Acid (mg/dL) 8.36 + 2.90 9.05 + 3.17 0.035
SVO2 (%) 55.65 + 8.55 55.59 + 9.52 0.953
Continuous variables are mean + standard deviation
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preperitoneally (72 (56.7%) vs 219 (60.5%)) placed LVADs
(P = 0.452).
The high WBC group (Table 5) had a longer length of in-
tensive care unit (ICU, P= 0.046) and a trend toward longer
total hospital stay (P= 0.064). There was more postoperative
renal failure requiring dialysis in the high WBC group
(P= 0.014), but no difference in subsequent permanent dialy-
sis (P= 0.611). Postoperatively (Table 5), the higher WBC
was more likely to experience right heart failure (13.4% vs
5.8%, P= 0.006), and need for a right ventricular assist device
(RVAD) (11.0% vs 4.4%, P= 0.008). Patients experiencing
postop RVF had a higher preop WBC (11.3 + 5.7 vs
8.7 + 3.1) and CRP (5.6 + 4.4 vs 3.3 + 4.7) levels. For those
who needed an RVAD, there was no difference in the dur-
ation of use (P= 0.452). There was also no difference in the
incidence (P= 0.950) and duration (P= 0.514) of nitric oxide
use (Table 5). After excluding patients who underwent pre-
operative TCS, patients who had postoperative RVF had a
higher preoperative WBC (10.3 + 4.4 vs 8.5 + 2.7, P= 0.002)
and CRP (5.3 + 4.3 vs 2.9 + 4.2, P= 0.014) compared to those
who did not. We performed a “Receiver Operating Charac-
teristics” analysis and shows that WBC and CRP was able to
predict RVF with a C-statistics of 0.661 (P= 0.001) and 0.727
(P < 0.001) respectively. There was no difference in other
complications or operative mortality (P > 0.05). The high
WBC group had poorer mid-term survival (Fig. 1, P= 0.042)
Table 2 Preoperative Hemodynamics and INTERMACS Class
WBC < 10.5 K/μL (n = 362) WBC > 10.5 K/μL (n = 127) P Value
HR (bpm) 86.13 + 16.72 94.91 + 19.11 <0.001
Mean Arterial BP (mmHg) 74.96 + 8.84 76.38 + 9.97 0.133
CO (L/min) 4.49 + 1.18 4.69 + 1.49 0.121
CI (L/min/m2) 2.25 + 0.55 2.32 + 0.67 0.291
PCWP (mmHg) 19.74 + 6.72 20.85 + 7.35 0.122
PAP (mmmHg)) 31.50 + 8.14 32.58 + 8.39 0.202
RAP (mmHg) 8.63 + 4.88 9.84 + 5.29 0.019
PVR (Wood Units) 2.78 + 1.38 2.84 + 1.69 0.704
SVR (dynes/sec/cm5) 1265.88 + 392.30 1253.54 + 478.32 0.776
TPG (mmHg) 11.76 + 4.83 11.70 + 4.81 0.899
RVSWI (gm/m/m2/beat) 615.46 + 269.14 551.54 + 226.69 0.011
CVP/PCWP Ratio 0.44 + 0.23 0.48 + 0.25 0.124
INTERMACS
1 37 (10.2%) 35 (27.6%) <0.001
2 90 (24.9%) 39 (30.7%) 0.198
3 188 (51.9%) 40 (31.5%) <0.001
4 47 (13.0%) 13 (10.2%) 0.417
Continuous variables are mean + standard deviation
Table 3 Preoperative Echocardiographic Findings, and Mechanical Support
WBC < 10.5 K/μL (n = 362) WBC > 10.5 K/μL (n = 127) P Value
LVEF (%) 15.33 + 5.78 15.40 + 5.60 0.900
Moderate-Severe RVD 182 (50.3%) 73 (57.3%) 0.162
Severe AI 14 (3.9%) 2 (1.6%) 0.211
Severe MR 123 (34.0%) 40 (31.5%) 0.610
Severe TR 53 (14.6%) 14 (11.0%) 0.308
Bridge to Txp 211 (58.3%) 89 (70.1%) 0.019
Destination 151 (41.7%) 38 (29.9%) 0.019
TCS 23 (6.4%) 22 (17.3%) <0.001
TCS Duration (median) 4.0 (IQR = 2.0) 6.0 (IQR = 4.0) 0.022
IABP 171 (47.2%) 71 (55.9%) 0.093
IABP Duration (median) 1.0 (IQR = 1.0) 2.0 (IQR = 3.0) 0.012
LVEF is expressed as mean + standard deviation. Other continuous variables were expressed as median with interquartile range
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with survival between the 2 groups diverging at approxi-
mately 2 years after cfLVAD implantation.
Discussion
Our studies demonstrate that in patients undergoing cfLVAD
implantation, those who have a higher WBC preoperatively
had a poorer postoperative and long term prognosis. The
CRP, another commonly measured lab value, was also ele-
vated consistent with a proinflammatory environment. While
there was no difference in creatinine, there were laboratory
evidence of liver dysfunction with elevations in total bilirubin
and INR in the high WBC group. Higher WBC was also
associated with a greater severity of heart failure with a
greater proportion of patient classified as INTERMACS Pa-
tient Profile 1, higher heart rate, lower right ventricular
stroke work index, as well as a greater incidence and dur-
ation of preoperative TCS. The high WBC group may be
younger because more of these patients presented with acute
cardiogenic shock and received temporary TCS with subse-
quent LVAD as bridge to transplant. Conversely, the older
group were more likely to have chronic heart failure treated
with destination therapy LVAD without the acute shock
presentation requiring TCS. Furthermore, younger patient
are more likely to mount a greater inflammatory response to
Table 4 Operative Procedures and Parameters
WBC < 10.5 K/μL (n = 362) WBC > 10.5 K/μL (n = 127) P Value
Redo-Sternotomy 103 (28.5%) 29 (22.8%) 0.220
Cardiopulmonary Bypass (min) 83.96 + 31.61 87.65 + 35.348 0.273
Sternum Closed 213 (58.8%) 82 (64.6%) 0.211
Chest Open (median days) 1.0 (IQR = 1.0) 1.0 (IQR = 1.0) 0.808
Concomitant Surgery
Valve procedure 161 (44.5%) 54 (42.5%) 0.702
AV procedure 27 (7.5%) 6 (4.7%) 0.291
TV Procedure 143 (39.5%) 49 (38.6%) 0.855
MV Procedure 2 (0.6%) 0 (0.0%) 0.401
Intrapericardial LVAD 143 (39.5%) 55 (43.3%) 0.452
Preperitoneal LVAD 219 (60.5%) 72 (56.7%) 0.452
Cardiopulmonary bypass time was expressed as mean + standard deviation. Chest open days is expressed as median with interquartile range
Table 5 Postoperative Outcomes
WBC < 10.5 K/μL (n = 362) WBC > 10.5 K/μL (n = 127) P Value
Total ICU LOS (mean days) 10.95 + 17.22 15.73 + 34.92 0.046
Total LOS (mean days) 26.06 + 20.15 30.86 + 35.58 0.064
Total Days Readmit (mean days) 38.14 + 54.11 31.94 + 45.47 0.248
Device Infection 95 (26.2%) 26 (20.5%) 0.195
Device Exchange Infection 21 (5.8%) 7 (5.5%) 0.904
Late AV Intervention 5 (1.4%) 1 (0.8%) 0.601
Stroke 94 (26.0%) 32 (25.2%) 0.864
Hemolysis 87 (24.0%) 28 (22.0%) 0.650
Postop Dialysis/CVVH 12 (3.3%) 11 (8.7%) 0.014
Postop Perm Dialysis 6 (1.7%) 3 (2.4%) 0.611
LVAD Death 107 (29.6%) 41 (32.3%) 0.565
Transplant 132 (36.5%) 42 (33.1%) 0.492
Operative Mortality 16 (4.4%) 8 (6.3%) 0.399
RV Failure 21 (5.8%) 17 (13.4%) 0.006
RVAD 16 (4.4%) 14 (11.0%) 0.008
Duration of RVAD (median) 17.0 (IQR = 18.0) 20.50 (IQR = 74.0) 0.452
Nitric Oxide Use 356 (98.3%) 125 (98.4%) 0.950
Nitric Duration (median days) 2.0 (IQR = 2.0) 2.0 (IQR = 2.0) 0.514
Hospital stay times are expressed as mean + standard deviation. Duration of RVAD and nitric oxide use is expressed as median with interquartile range
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cardiovascular stress in the LVAD setting as immunosenes-
cence and dysfunction of the immune system progresses
with aging [12].
The higher WBC may be attributed to the greater
underlying acuity with likely more inotropic support as
well as need for TCS preoperatively. Blood contact with
artificial surfaces during pre-cfLVAD mechanical support
induces an increase in chemokines and cytokines such
as IL-8, MCP-1, MIP-1β, IP-10, GM-CSF [13]. This ele-
vated preoperative inflammatory milieu in our study popula-
tion is correlated with a greater incidence of RVF (5.8% vs
13.4%, P = 0.006) and need for RVAD (4.4% vs 11.0%) post-
operatively. Cytokines such as TNF-α and its receptor has
been shown to be upregulated in the failing myocardium
[14]. Its role in causing myocardial dysfunction has been
demonstrated where TNF-receptor-associated factor 2
(TRAF2) expression lead to heart failure, and this can be re-
versed after removal of inflammatory stimulus [15]. Further-
more, increased TNF-α levels are associated with greater
nonsurgical bleeding following LVAD implantation [16].
Many previous studies have focused on postoperative
inflammatory status on prognosis. Inflammatory cytokines
were higher in nonsurvivors over 30 days post-LVAD
implantation. In particular TNF-α, IL-1β, and IL-8 were
elevated within hours to 7 days postoperatively [17]. Our
finding that the high WBC group had a higher ICU and
total hospital length of stay is consistent with prior find-
ings where patients with higher preoperative IL-6, IL-8
and neopterin levels had a longer ICU stay and a greater
decline in end organ function [18]. This impact on end
organ dysfunction is reflected in our study where higher
preoperative WBC was associated with a greater incidence
of postoperative dialysis.
Interestingly, the high WBC group also had a greater
proportion of patients that were bridged to transplant-
ation consistent with a more severe heart failure with
likely a higher incidence of biventricular dysfunction.
Furthermore, our study showed that elevation in
pre-cfLVAD WBC has long terms implications with a
poorer mid-term survival that becomes evident 2 years
after cfLVAD implantation. Late RVF may be a possible
explanation for this finding.
The association of a preoperative proinflammatory
state (elevated WBC and CRP) with the occurrence of
postoperative RVF provides insights into the clinical
relevance of inflammation in impacting myocardial
Fig. 1 Kaplan-Meier Survival for patients with low and high WBC pre-LVAD implantation
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contractility. Given the limited predictive value of
current post-LVAD RVF prediction models, preoperative
inflammatory markers may need to be incorporated into
the algorithm for improved accuracy. It is also possible
that suppression of excessive preoperative inflammation
can decrease the incidence of RVF and need for RVAD.
This study has limitations due to its retrospective nature in
a single institution with inherent limitations and biases. Ele-
vation in WBC may reflect a higher INTERMACS status
with greater inotrope use, use of TCS and the stress of a
greater degree of heart failure. It remains unclear whether an
independent elevation in WBC reflecting a greater inflam-
matory status is causative for poorer postoperative and long
term outcomes. We cannot definitively exclude the likeli-
hood of infection playing a role in elevated WBC since only
a minority of patients have microbiological work up to ex-
clude this possibility. Furthermore, it is possible that steroids
used to treat inflammatory cardiomyopathies (e.g. giant cell
myocarditis) preoperative may have contributed to elevated
WBC. While there was a difference in age, high WBC group
was younger but still had a poorer survival despite this. We
acknowledge that there are multiple preoperative factors that
may cause elevations in WBC and CRP, this introduces het-
erogeneity into our study groups.
Conclusions
Our study demonstrates that a preoperative proinflammatory
milieu characterized by elevations of WBC and CRP can be
associated with postoperative RVF. Increased WBC was also
associated with a longer length of hospital and ICU stay, a
higher incidence of postoperative dialysis, as well as poorer
long term patient survival. Preoperative proinflammatory
stimuli likely include temporary mechanical support, cate-
cholamines, concurrent infection, and low cardiac output
syndrome with tissue ischemia. Leukocytosis is likely a
marker of tissue stress and hypoperfusion. Furthermore, it is
well recognized that inflammation can have a negative im-
pact on myocardial contractility with implications for RVF
after LVAD implantation.
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